Zynerba flunks another PhII trial, all but ending Fragile X hopes

Zynerba’s CBD drug has failed its fourth trial in as many years.

In a pivotal Phase II trial, their lead compound failed to significantly improve behavioral symptoms in patients with Fragile X syndrome, missing both the primary endpoint and three different secondary endpoints.